Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 22:5:2908.
doi: 10.12688/f1000research.9717.1. eCollection 2016.

Recent advances in understanding antiphospholipid syndrome

Maria Laura Bertolaccini  1 , Giovanni Sanna  2
Affiliations
Review

Recent advances in understanding antiphospholipid syndrome

Maria Laura Bertolaccini et al. F1000Res. .

Abstract

Antiphospholipid syndrome (APS), also known as Hughes Syndrome, is a systemic autoimmune disease characterized by thrombosis and/or pregnancy morbidity in the presence of persistently positive antiphospholipid antibodies. A patient with APS must meet at least one of two clinical criteria (vascular thrombosis or complications of pregnancy) and at least one of two laboratory criteria including the persistent presence of lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and/or anti-b2 glycoprotein I (anti-b2GPI) antibodies of IgG or IgM isotype at medium to high titres in patient's plasma. However, several other autoantibodies targeting other coagulation cascade proteins (i.e. prothrombin) or their complex with phospholipids (i.e. phosphatidylserine/prothrombin complex), or to some domains of β2GPI, have been proposed to be also relevant to APS. In fact, the value of testing for new aPL specificities in the identification of APS in thrombosis and/or pregnancy morbidity patients is currently being investigated.

Keywords: APS; Hughes Syndrome; antiphospholipid syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no completing interests. No competing interests were disclosed. No competing interests were disclosed.

References

    1. Miyakis S, Lockshin MD, Atsumi T, et al. : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. 10.1111/j.1538-7836.2006.01753.x - DOI - PubMed
    1. Hughes GR: Hughes' syndrome: the antiphospholipid syndrome. A historical view. Lupus. 1998;7(Suppl 2):S1–4. - PubMed
    1. Abreu MM, Danowski A, Wahl DG, et al. : The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. 10.1016/j.autrev.2015.01.002 - DOI - PubMed
    1. Wilson WA, Gharavi AE, Koike T, et al. : International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11. 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F - DOI - PubMed
    1. Galli M, Luciani D, Bertolini G, et al. : Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32. 10.1182/blood-2002-02-0441 - DOI - PubMed

LinkOut - more resources